The FDA on August 9, 2023, granted regular approval to GAVRETO® for adult patients with metastatic REarranged during Transfection (RET) fusion-positive Non-Small Cell Lung Cancer (NSCLC) as detected by an FDA-approved test. GAVRETO® is a product of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
